Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00013546 · ClinicalTrials.gov registry record · Phase 2
Hormone Replacement Therapy to Treat Turner Syndrome
A Phase 2 study of Osteoporosis and Turner's Syndrome, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT00013546 is a Phase 2 study of Osteoporosis and Turner's Syndrome that has completed, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 92 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00013546, a Phase 2 study of Osteoporosis and Turner's Syndrome, has completed, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effects of hormone replacement therapy on patients with Turner syndrome (TS)-a genetic disorder in females in which part or all of one X chromosome is missing. Most girls and women with TS have underdeveloped ovaries-the female reproductive organs that produce the female sex hormones estrogen and progesterone, and smaller amounts of the male sex hormone, testosterone. These hormones affect muscle and bone strength, sex drive, energy, and an overall sense of well being. Estrogen may also play a role in memory and mood and have a protective effect against heart disease. Women with TS have a much higher risk of developing osteoporosis (loss of bone density), high blood pressure, high cholesterol and diabetes than women without this disorder. Girls and women with Turner syndrome between the ages of 14 and 50 years may be eligible for this 2-year study. Three months before beginning treatment, all patients will wear an estrogen patch and take a progesterone tablet daily for 10 days each month. They will then be randomly assigned to one of two treatment groups to compare the effects of estrogen alone with estrogen plus testosterone on bone strength, muscle and fat mass and psychosocial well being. Both groups will wear an estrogen patch and take oral progesterone. One group will also wear a testosterone patch while the other group will wear a placebo patch (a patch that does not contain any testosterone). Neither study participants nor the doctors will know who is getting the testosterone until the study is complete. Patients will undergo the following procedures before beginning treatment and at 6, 12 and 24 months after starting treatment: * Physical examination. * DEXA scans (dual energy X-ray absorptiometry) to measure body composition and bone thickness. Low radiation X-rays scan the whole body to measure fat, muscle and bone mineral content.. * Magnetic resonance imaging (MRI) scan of the abdomen to measure the amount of fat around the
Conditions Studied
Interventions
- DRUG TMTDS
Study Locations (1)
Maryland
- National Institute of Child Health and Human Development (NICHD) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2001-03 |
| Est. Completion | 2002-12 |
| Phase | Phase 2 |
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)305 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00013546
The ClinicalTrials.gov registry entry for NCT00013546 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (94% lower). The listed sponsor is Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Osteoporosis appearing as the primary indexed condition, and to 1 intervention - of which TMTDS is the first listed.
NCT00013546 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00013546 about?
NCT00013546 is a clinical study titled "Hormone Replacement Therapy to Treat Turner Syndrome". This study will evaluate the effects of hormone replacement therapy on patients with Turner syndrome (TS)-a genetic disorder in females in which part or all of one X chromosome is missing. Most girls and women with TS have underdeveloped ovaries-the female reproductive organs that produce the female...
What is the current status of trial NCT00013546?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2001-03. Estimated completion is 2002-12.
What conditions does trial NCT00013546 study?
This clinical trial studies the following conditions: Osteoporosis, Turner's Syndrome.
What interventions are being tested in trial NCT00013546?
The interventions under investigation include: TMTDS (DRUG).
Who is sponsoring clinical trial NCT00013546?
This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00013546 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
RECRUITING · Phase 2
-
Calcium and Bone Mass in Young Females
COMPLETED · Phase 2
-
Comparison Study of PTHrP and PTH to Treat Osteoporosis
COMPLETED · Phase 2
-
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
COMPLETED · Phase 2
-
12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)
COMPLETED · Phase 2
-
Adding Phosphorus to Osteoporosis Drug Treatment
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.